tirzepatide vs semaglutide price Semaglutide: Weight Loss Winner? 🏆 📊 72-Week NEJM Data: Tirzepatide: ~20% body weight loss Semaglutide: ~14% body weight loss 💡 Tirzepatide shows greater weight & HbA1c reduction, but cost, side Zepbound vs Wegovy: Tirzepatide vs

Vous ne trouvez pas le mdicament dont vous avez besoin

Keep a simple record

GLP-1 medications simulate the natural hormone produced in the intestines that helps you feel full after you eat

Today weight problems and diseases associated with it are rather widespread, therefore, information on these options become useful when determining which of them is more suitable for a person

Your weekends remain fully available for activities, exercise, socializing, and eating normally

RCT SUMMIT - Tirzepatide vs Placebo for Heart Failure with Preserved Ejection Fraction and Obesity, NEJM (2024) [PubMed abstract] The SUMMIT trial enrolled 731 patients with heart failure, an ejection fraction of at least 50%, and a BMI of 30 or more Main inclusion criteria Age 40 years NYHA class II-IV EF 50% BMI 30 KCCQ-CSS of 80 or lower Main exclusion criteria Cardiomyopathy Uncontrolled hypertension History of bariatric surgery HbA1c 9.5% Baseline characteristics Age - 65.3 years Female sex - 53.8% NYHA class: II - 72.5% | III or IV - 27.5% Average body weight - 227 lbs (103 kg) Average BMI - 38.3 Average EF - 60.8% History of CAD - 30% Median NT-proBNP level - 183 pg/ml Average GFR - 64.4 ml/min Average KCCQ-CSS score - 53.6 Heart failure exacerbation within 12 months - 46.9% Atrial fibrillation - 25.5% Type 2 diabetes - 48.2% Randomized treatment groups Group 1 (364 patients): Tirzepatide with a target dose of 15 mg once weekly Group 2 (367 patients): Placebo Tirzepatide was started at 2.5 mg once weekly and increased by 2.5 mg every 4 weeks as tolerated (1) Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event